Sat, Nov 29, 2014, 4:46 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vringo, Inc. Message Board

edvacourt 7 posts  |  Last Activity: Nov 24, 2014 10:46 AM Member since: Oct 23, 2012
  • Reply to

    Valuation

    by buckmaker07 Nov 24, 2014 9:50 AM
    edvacourt edvacourt Nov 24, 2014 10:46 AM Flag

    Much more. I know that is difficult to envision for most people but it won't be in 3-6 months time.

    Sentiment: Strong Buy

  • Reply to

    AEMD: India Math

    by edvacourt Nov 23, 2014 3:56 PM
    edvacourt edvacourt Nov 23, 2014 8:40 PM Flag

    Sorry, report was a World Bank report not WHO

    Sentiment: Strong Buy

  • Reply to

    AEMD: India Math

    by edvacourt Nov 23, 2014 3:56 PM
    edvacourt edvacourt Nov 23, 2014 8:31 PM Flag

    I get the comment, yes, which is why I used such a modest penetration number. A report by the World Health Organization from 2012 put 25% of India's population having access to healthcare with 50% projected by 2015. As I said, the per treatment cost is likely to come down with mass production but it is likely the percentage treated will go up. Point being that $2b for one indication in one country makes the revenue possibilities both dynamic and dramatic.

    Sentiment: Strong Buy

  • edvacourt by edvacourt Nov 23, 2014 3:56 PM Flag

    Something to consider as we await the Medicity study results. There are some 12 Million cases of Hepatitis C in India currently. If just 2% of that number receive one, three-day, treatment protocol with the Hemopurifier annually, we are talking 240,000 treatments at a known current cost of $7,400 per treatment. That yields approximately $1.7b in treatment revenue. Of course once the Hemopurifier is mass produced costs may be reduced but it's also possible 5-10% of all cases receive treatment. Critically, this is just one of dozens of indications that the Hemopurifier may ultimately be able to treat and in only one country (India) if talking about Hep C's 150M+ cases worldwide. If the upcoming results are as many suspect, hard to imagine that AEMD is not soon valued in the billions. I strongly suspect we are looking at a once in a generation kind of company here.

    Sentiment: Strong Buy

  • Reply to

    Near Term Clinical Progression Goals

    by searleg Nov 20, 2014 11:40 AM
    edvacourt edvacourt Nov 20, 2014 12:41 PM Flag

    I agree with your assessment vvvvv-the Hep C results should really move AEMD. In my view AEMD is extraordinarily undervalued at this moment. Market Cap could have a "b" after it at some point next year. There are too many examples of biotechs that have that kind of value, are pre-revenue and don't seem to have anything like the potential of Aethlon.

    Sentiment: Buy

  • edvacourt by edvacourt Nov 3, 2014 10:07 AM Flag

    One of the things many people have worried about over time is that HYSR seems to operate in a bubble and other than the UCSB deal and some advancement pronouncements basically there isn't much to show for anything. The announcement this morning that the University of Iowa is now engaged as well can only be viewed as an affirmation of the science and perhaps a sign that Hypersolar is moving into the stage where they have a real shot at the 1.5V level. The prior announcement that they had figured out how to separate hydrogen and oxygen gas bubbles in the same reactor we believe is a precursor to an update on the voltage itself. It is quite possible with this new agreement in place that the next announcement we hear will have something to do with voltage level. It also seems appropriate that that would come after today's announcement. As always do your own due diligence.

    Sentiment: Strong Buy

  • edvacourt by edvacourt Oct 21, 2014 10:09 AM Flag

    To develop a safer shortcut is perhaps among the biggest things one can announce in scientific exploration. The good news about this is that it is likely just the first in a series of announcements. Many have screamed that HYSR has been too slow but science is painstaking and it can't be rushed. I'd say for a little group like HYSR that is trying to make history they have come a long way in a short period of time. UCSB must be very proud today as well. I look for this to test the highs again in the next couple of months.

    Sentiment: Strong Buy

VRNG
0.9718+0.0996(+11.42%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
BP p.l.c.
NYSEFri, Nov 28, 2014 1:02 PM EST